Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer

Trial Profile

Research on biomarkers in cetuximab containing combination therapies for patients with KRAS wild-type metastatic colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Gimeracil/oteracil/tegafur; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 02 Jun 2017 Results assessing the association between the neutrophil-lymphocyte ratio and clinical outcome (n=71), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 09 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top